Skip to main content

Outlook Therapeutics, Inc. (OTLK)

NASDAQ: OTLK · IEX Real-Time Price · USD
-0.02 (-0.94%)
After-hours:Oct 20, 2021 5:20 PM EDT
0.03 (1.42%)
At close: Oct 20, 4:00 PM

Company Description

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.

Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases.

Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte.

Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018.

Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Outlook Therapeutics, Inc.
Outlook Therapeutics Logo
CountryUnited States
IPO DateMay 13, 2016
SectorHealth Care
CEOLawrence Kenyon

Contact Details

485 Route 1 South
Iselin, New Jersey 08830
United States
Phone609 619 3990

Stock Details

Ticker SymbolOTLK
Fiscal YearOctober - September
Reporting CurrencyUS Dollars
CIK Code0001649989
CUSIP Number68235M105
ISIN NumberUS69012T2069
Employer ID38-3982704

Key Executives

Ralph H. ThurmanIndependent Executive Chairman
Lawrence A. Kenyon CPAChief Financial Officer, Treasurer, Company Secretary and Director
Terry DagnonChief Operating Officer
Jeffrey EvansonChief Commercial Officer
C. Russell Trenary IIIPresident, Chief Executive Officer and Director
Rick GregoryDirector of Marketing and Communications
Dr. Balu N. BalasubramanianAdvisor
Elizabeth A. YamashitaAdvisor